| |
|
|
|
|
|
Zymeworks Announces Positive Topline Data in the Pivotal HERIZON-BTC-01 Trial of Zanidatamab
|
|
Vancouver, BC, December 21, 2022--Zymeworks Inc., a clinical-stage biotechnology company developing multifunctional biotherapeutics, announced positive topline results from the pivotal Phase 2b HERIZON-BTC-01 open-label, single-arm clinical trial investigating zanidatamab, a HER2-targeted bispecific antibody, as monotherapy in patients with previously treated HER2-amplified and expressing BTC.
|
|
|
|
|
|
|
|
Zymeworks Provides Corporate Update and Reports Q3 2022 Financial Results
|
|
Vancouver, BC, November 21, 2022--Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, reported financial results for the third quarter ended September 30, 2022. The company also completed its plan to become a Delaware domiciled corporation.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Zymeworks Announces Plan To Become A Delaware Corporation
|
|
Vancouver, BC, July 25, 2022--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, has announced its intention to become a Delaware corporation ("New Zymeworks"), subject to receipt of necessary shareholder, stock exchange, and court approvals.
|
|
|
|
|
|
|
|
Zymeworks Appoints Dr. Paul Moore As Chief Scientific Officer
|
|
Vancouver, BC, July 21, 2022--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, announced that it is strengthening its senior leadership team with the appointment of Paul Moore, Ph.D., as Chief Scientific Officer, reporting directly to the Chief Executive Officer.
|
|
|
|
|
|
|
|
|
News
Events
Tech Careers
Directory
Tech Stocks
T-Net 100
Members
Feedback
About T-Net
Employers
Post Job Listings
Advertise
